Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Working in collaboration with the ... London , Richmond Pharmacology is the first centre ... study for an investigational RNAi therapeutic being developed for the ... nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... March 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... on providing advanced testing solutions for the detection ... for the three months and full year ended ... Financial Results:Revenue for the quarter ended December 31, ... the fourth quarter of 2013 and $1.5 million ...
(Date:3/26/2015)... 26, 2015  BioNano Genomics, Inc., the leader in ... as chief commercial officer. Salyer has more than ... teams in life sciences. At BioNano, Salyer will oversee ... genome-mapping platform to assemble a comprehensive view of complex ... date, 32 institutions located in the United ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... bacteria, Duke University chemists and engineers have introduced a ... create microdevices such as labs-on-a-chip. , Their inkless microcontact ... nanometer, or billionths of a meter, the Duke team ... Journal of Organic Chemistry. , "This has a ...
... (Nasdaq:,SIAL) is pleased to announce that Patrick M. ... for the Research Biotech business unit, effective,October 1, ... Sigma-Aldrich,s,leadership position through the development of new and ... involved with Sigma-Aldrich,since 2005 as a member of ...
... BIOM ),(TSX: BRA) (the "Company") today announced that, ... in the United States, it intends,to change its name ... shareholder and court approval of a plan of arrangement, ... parent corporation,of a successor corporation of the current Biomira ...
Cached Biology Technology:Using catalysts to stamp nanopatterns without ink 2Using catalysts to stamp nanopatterns without ink 3Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech 2Biomira announces plan to change name to Oncothyreon 2Biomira announces plan to change name to Oncothyreon 3Biomira announces plan to change name to Oncothyreon 4Biomira announces plan to change name to Oncothyreon 5Biomira announces plan to change name to Oncothyreon 6
(Date:3/12/2015)... 2015 The mascots of the Atlantic Coast ... of Wake Forest Baptist Medical Center. They stopped by ... ACC Men,s Basketball Tournament. Young patients enjoyed bonding with ... their autographs. Brenner Children,s Hospital is the ... only children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
(Date:3/10/2015)... OXFORD, Conn. , March 10, 2015 /PRNewswire/ ... NXTDW) ("NXT-ID" or the "Company"), a biometric authentication ... reports the company,s Wocket™ smart wallet has been ... 2015" by Rethink Modern. Rethink Modern ... sharing modern and innovative items for your home and lifestyle that ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... Mutations in a single gene can cause several ... considered different disorders. With support from the National ... exome sequencing a new gene scanning technology that ... mutations. "This is going to change the way ...
... Disease A new compound may offer an effective ... researchers from Brazil. They report their findings in the ... Chemotherapy . Chagas, disease is an infection caused by ... 18 million people and causes up to 50,000 deaths per ...
... , Global plant productivity that once was on the rise ... on the decline because of regional drought according to a ... is a measure of the rate of the photosynthesis process ... and water to sugar, oxygen and eventually plant tissue. Compared ...
Cached Biology News:Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Drought drives decade-long decline in plant growth 2
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... power supply (Cat. No. Minis 150VS) is ... meet most electrophoresis needs in a personal, ... 150V power supply is capable of running ... designed for individuals to have his/her own ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: